Skip to main content
SpringerLink
Log in

Mammakarzinom: Individualisierung der adjuvanten Therapie

Aktuelle Studien zu molekularen Techniken

Breast carcinoma: individualization of adjuvant therapy

Current studies on molecular techniques

  • Gynäkologie aktuell
  • Published:
Der Gynäkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Goldhirsch A et al (2009) Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20(8):1319–1329

    Article  CAS  PubMed  Google Scholar 

  2. Early Breast Cancer Trialists‘ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717

    Article  Google Scholar 

  3. Vijver MJ van de et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009

    Article  PubMed  Google Scholar 

  4. Look MP et al (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94(2):116–128

    CAS  PubMed  Google Scholar 

  5. Harbeck B, Meisner SMC (2009) Final 10-year analysis of prospective multicenter Chemo N0 trial for validation of ASCO-recommended biomarkers uPA/PAI-1 for therapy decision making in node-negative breast cancer. J Clin Oncol 27(No 15S (May 20 Supplement)):511

    Google Scholar 

  6. Annecke K et al (2008) uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem 45:31–45

    Article  CAS  PubMed  Google Scholar 

  7. ASCO, G., ASCO Guidelines. http://www.asco.org

  8. Arbeitsgemeinschaft Gynäkologische Onkologie, Leitlinien, AGO-Leitlinien. http://www.ago-online.de

  9. http://www.senologie.org/leitlinien.php

  10. Paik S et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Frauenklinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Aachen, RWTH, Pauwelsstr. 30, 52074, Aachen, Deutschland

    B. Bruno, N. Maass &  D.O. Bauerschlag

Authors
  1. B. Bruno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Maass
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D.O. Bauerschlag
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D.O. Bauerschlag.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bruno, B., Maass, N. & Bauerschlag, D. Mammakarzinom: Individualisierung der adjuvanten Therapie. Gynäkologe 43, 940–944 (2010). https://doi.org/10.1007/s00129-010-2674-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-010-2674-6

Search

Navigation